Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Total Current Liabilities
All obligations due within one year.
Benitec Biopharma Inc.NASDAQ: BNTC
Total Current Liabilities · Q3 FY2026 · quarter ended Mar 2026
Total current liabilities falls 53.4% from a year ago
Total current liabilities stood at $3.27M at the end of Q3 FY2026, down 53.4% from a year earlier and up 16.9% from the prior quarter. Over 3 fiscal years it compounded at -10.7% a year.
Context
- Total current liabilities amounted to 1.8% of total assets at the end of Q3 FY2026, down 4.9 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -53.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.8M USD
- Year-over-year change
- -63.4%
- 4-year CAGR
- +7.1%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 1.8M | -63.4% |
| FY2024 | 2024-06-30 | 4.92M | +23.8% |
| FY2023 | 2023-06-30 | 3.98M | +57.1% |
| FY2022 | 2022-06-30 | 2.53M | +85.0% |
| FY2021 | 2021-06-30 | 1.37M | — |
Total Current Liabilities vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 total current liabilities of $3.27M is the lowest of the 10 companies compared; the peer median is $20.71M.
- Its year-over-year change of -53.4% is the 9th highest of 10, against a peer median of +5.2%.
- Total current liabilities amounts to 1.8% of total assets for BNTC, versus a peer median of 8.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $63.6M | -4.5% | +16.6% | 12.1% | |
| Dec 2025 | $46.31M | +11.9% | -21.8% | 8.7% | |
| Mar 2026 | $33.08M | +61.9% | +72.2% | 12.2% | |
| Mar 2026 | $30.28M | +5.2% | +14.1% | 7.2% | |
| Mar 2026 | $20.71M | +22.6% | -6.9% | 36.4% | |
| Mar 2026 | $18.87M | +33.9% | +35.1% | 7.2% | |
| Mar 2026 | $10.71M | -14.8% | +13.6% | 5.0% | |
| Mar 2026 | $8.15M | -37.7% | -15.7% | 7.4% | |
| Mar 2026 | $7.31M | -93.4% | -14.9% | 46.4% | |
| Mar 2026 | $3.27M | -53.4% | -10.7% | 1.8% | |
| Peer median (excluding BNTC) | $20.71M | +5.2% | +13.6% | 8.7% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.